Clinical trials
Liver Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting liver cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,778 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07285382RecruitingPhase 2
Dalpiciclib plus letrozole for advanced HR+ HER2- breast cancer
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
Dalian, LiaoningAges 18–75 - NCT07302763Recruiting
PET imaging to track prostate cancer changes
This study uses special PET scans (up to 4 times) to see how metastatic prostate cancer changes over time. It is for people whose cancer has spread and is still growing after hormone treatments, and who are planning to start chemotherapy or PSMA therapy.
Québec, QuebecAges 18 years+ - NCT07309276RecruitingPhase 2
Study of JS212 for advanced lung cancer
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07309289RecruitingPhase 3
Comparing two drug combos for first-line metastatic colorectal cancer
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
ShanghaiAges 18 years+ - NCT07309770RecruitingPhase 2
Trastuzumab Rezetecan for advanced solid tumors that have stopped responding to standard treatments
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07311694RecruitingPhase 3
Comparing a new treatment with standard drugs for advanced prostate cancer
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07333066RecruitingPhase 3
Adding chemotherapy when first treatment response is limited
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
BayonneAges 18 years+ - NCT05099172RecruitingPhase 1/Phase 2
Study drug for EGFR or HER2-mutated advanced lung cancer
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
Gilbert, ArizonaAges 18 years+ - NCT05376878RecruitingPhase 4
PET/MRI scan to guide treatment in HER2+ brain metastatic breast cancer
This trial tests a special PET/MRI imaging scan using a labeled drug to help doctors evaluate HER2+ breast cancer that has spread to the brain. It focuses on patients who plan to receive fam-trastuzumab deruxtecan, a targeted cancer medicine, and aims to see how well the scan can support treatment decisions.
Duarte, CaliforniaAges 18 years+ - NCT04804644RecruitingPhase 3
Memory-sparing radiation for brain metastases in small cell lung cancer
This study tests whether focusing high-dose radiation only on brain tumor spots, while avoiding the hippocampus (a brain area important for memory), helps protect memory and thinking compared with standard whole-brain radiation. It’s for people with small cell lung cancer that has spread to the brain.
Phoenix, ArizonaAges 18 years+ - NCT07527858RecruitingPhase 2
Study of Denikitug with immunotherapy or chemotherapy for advanced colorectal cancer
This trial tests a new drug called denikitug, given alone or combined with other cancer treatments, for patients with advanced colorectal cancer that hasn't responded to previous treatments. The goal is to help people whose cancer has a specific genetic profile (MSS) that doesn't respond well to standard immunotherapy alone.
North Haven, ConnecticutAges 18 years+ - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
Dothan, AlabamaAges 18 years+ - NCT07361003RecruitingPhase 3
Testing suvemcitug plus chemo for refractory colorectal cancer
This trial tests a new drug, suvemcitug, combined with an oral chemotherapy called FTD/TPI for people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07369882Recruiting
Less extensive surgery after immunotherapy for advanced head and neck cancer
This trial compares a less extensive surgery to the standard surgery for patients with advanced head and neck cancer who have responded well to initial chemotherapy and immunotherapy. The goal is to see if a smaller operation can be just as effective while causing fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT07391618RecruitingPhase 2
First treatment for advanced colorectal cancer with combo chemo
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
BeijingAges 18–75 - NCT07394062Recruiting
Comparing chemo-immunotherapy combinations for advanced lung cancer
This study compares two standard treatments for metastatic non-small cell lung cancer when the tumor has low levels of a protein called PD-L1. It looks at how well chemotherapy plus pembrolizumab works versus chemotherapy plus nivolumab and ipilimumab.
AnkaraAges 18 years+ - NCT03129854Recruiting
ADT with or without freezing the prostate for spread cancer
This trial compares standard hormone therapy (ADT) alone versus ADT plus a procedure that freezes the prostate (cryoablation) in people whose prostate cancer has spread. It looks to see whether adding freezing improves outcomes while keeping treatment safe.
Guangzhou, GuangdongAges 18–90 - NCT07510308RecruitingPhase 1
Vaccine trial for advanced colorectal cancer
This trial tests a personalized vaccine made from your own tumor cells for advanced colorectal cancer that is mismatch repair proficient (pMMR). It aims to see if the vaccine can help when standard treatments have stopped working.
Chengdu, SichuanAges 18–75 - NCT07427394RecruitingPhase 2
Camizestrant and atirmociclib for advanced breast cancer
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
St Louis, MissouriAges 18 years+ - NCT07450599RecruitingPhase 2
Darolutamide plus hormone therapy before prostate cancer surgery
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
Hefei, AnhuiAges 18 years+ - NCT07451002Recruiting
Study on Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer
This study looks at how well men with prostate cancer that has spread and is still hormone-sensitive stick to taking the drug apalutamide. It aims to understand real-world use and quality of life.
CaenAges 18 years+ - NCT07455903RecruitingPhase 2
Hormone therapy before surgery for high-risk prostate cancer
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
Miami, FloridaAges 18 years+
Hear when a new Liver Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,778 recruiting liver cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Locally Advanced Rectal Cancer
- Locally Advanced Cervical Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.